AGMB AgomAb Therapeutics NV
AgomAb Therapeutics NV (AGMB) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: October 8, 2026 , by Epstein David R .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Epstein David R | Director | Buy | 5,000 | $8.90 | $44.5K | 15,000 | |
| Kemula Pierre Thadee Victor 3 fills | Chief Financial Officer | Buy | 10,000 | $8.59 | $85.9K | 10,000 | |
| Knotnerus Tim Jasper | Chief Executive Officer | Buy | 5,000 | $8.70 | $43.5K | 21,823 | |
| Epstein David R | Director | Buy | 5,000 | $8.70 | $43.5K | 10,000 | |
| Knotnerus Tim Jasper | Chief Executive Officer | Buy | 6,000 | $8.48 | $50.9K | 16,823 | |
| Epstein David R | Director | Buy | 5,000 | $8.57 | $42.9K | 5,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.